A Phase 1 interventional study of TQB3702 tablets in Hematologic Malignancy, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-09.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Hematologic Neoplasms with a site in China — 76 open to participants now, 84 under way, 8 of them phase 3. Hematologic Neoplasms · China.
Among the 149 studies in Hematologic Neoplasms with a site in China, this one is the 32nd largest by planned enrollment of the 123 interventional ones that give a count, is one of 18 that started in 2022, is one of 57 in phase 1, and was the 68th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →76 of the 149 studies in Hematologic Neoplasms with a site in China are open now. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Chinese PLA General Hospital · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 79 · Phase 2 41 · Phase 3 15 · Phase 4 5
First in 2008; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 137 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 56 across the 123 interventional studies, 75 across the 25 observational. Of the 32 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 149 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
Sino Biopharmaceutical Limited has 6 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
19 of the studies in Hematologic Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07014449Hangzhou Weben Pharma Co., LtdClinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | 2026-12 |
| NCT06066203Sichuan Baili Pharmaceutical Co., Ltd.A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | 2026-12 |
| NCT04588922Sellas Life Sciences GroupStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | 2026-12-30 |
| NCT06225856Shanghai Yuyao Biotech Co., Ltd.An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies | 2026-12-30 |
| NCT05255926Zhongnan HospitalCXCR4-targeted PET/CT Imaging in Hematological Malignancies | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 149 studies in Hematologic Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the tolerability and preliminary efficacy of TQB3702 tablets in hematological tumor subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TQB3702 tablets were administered orally, 28 days as a treatment cycle until the progressive diseases or the investigator judges that it is not suitable for subject to continue to take this medicine.
Drug: TQB3702 tablets
TQB3702 tablets are selective BTK inhibitors.
Maximum tolerated dose (MTD)
To evaluate the maximum tolerated dose of TQB3702 tablets in the treatment of relapsed/refractory hematologic tumors.
Time frame: Baseline up to 104 weeks
Dose limited toxicity (DLT)
To evaluate the dose-limiting toxic dose of TQB3702 tablets in the treatment of relapsed/refractory hematologic tumors.
Time frame: Baseline up to 104 weeks
Recommended Phase II Dose (RP2D)
To evaluate the phase II recommended dose of TQB3702 tablets in the treatment of relapsed/refractory hematological tumors.
Time frame: Baseline up to 104 weeks
Time to Reach the Maximum Plasma Concentration (Tmax)-single dose
Time to Reach the Maximum Plasma Concentration after single dose
Time frame: before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Time to Reach the Maximum Plasma Concentration (Tmax)-multiple dose
Time to Reach the Maximum Plasma Concentration after multiple dose
Time frame: before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Maximum plasma concentration (Cmax)-Single dose
Cmax is the maximum plasma concentration of TQB3702 after single dose
Time frame: before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Maximum plasma concentration (Cmax)-Multiple dose
Cmax is the maximum plasma concentration of TQB3702 after multiple dose
Time frame: before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Elimination half-life (t1/2)-Single dose
t1/2 is time it takes for the blood concentration of TQB3702 or metabolite(s) to drop by half after single dose.
Time frame: before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72 hours after administration.
Elimination half-life (t1/2)-Multiple dose
t1/2 is time it takes for the blood concentration of TQB3702 or metabolite(s) to drop by half after multiple dose.
Time frame: before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Area under the plasma concentration-time curve from time zero to time t (AUC0-t)-Single dose
To characterize the pharmacokinetics of TQB3702 by assessment of area under the plasma concentration time curve from the first dose to a certain time.
Time frame: before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Area under the plasma concentration-time curve from time zero to time t (AUC0-t)-Multiple dose
To characterize the pharmacokinetics of TQB3702 by assessment of area under the plasma concentration time curve from the first dose to a certain time.
Time frame: before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)-Single dose
Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss) after Single dose
Time frame: before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)-Multiple dose
Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss) after Multiple dose
Time frame: before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
steady state area under the concentration-time curve over a dosing interval (AUCtau, ss)-single dose
steady state area under the concentration-time curve over a dosing interval (AUCtau, ss) after single dose
Time frame: before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
steady state area under the concentration-time curve over a dosing interval (AUCtau, ss)-multiple dose
steady state area under the concentration-time curve over a dosing interval (AUCtau, ss) after multiple dose
Time frame: before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Minimum steady-state plasma drug concentration during a dosage interval (Css-min)-Single dose
Minimum steady-state plasma drug concentration during a dosage interval (Cmin-ss) after Single dose
Time frame: before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Minimum steady-state plasma drug concentration during a dosage interval (Css-min)-multiple dose
Minimum steady-state plasma drug concentration during a dosage interval (Cmin-ss) after multiple dose
Time frame: before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Objective Response Rate (ORR)
The proportion of patients with tumor size reduction of a predefined amount and for a minimum time period
Time frame: Baseline up to 104 weeks
Complete Remission Rate (CRR)
The proportion of tumors that have a complete response after treatment
Time frame: Baseline up to 104 weeks
Disease Control Rate (DCR)
The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a cancer treatment in clinical trials.
Time frame: Baseline up to 104 weeks
Duration of Response (DOR)
The time from the date of first documentation of a CR or PR or PD to the date of first documentation of tumor progression.
Time frame: Baseline up to 104 weeks
Progression Free Survival (PFS)
The time from the first dose to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first
Time frame: Baseline up to 104 weeks
Overall Survival (OS)
the time from start of study treatment to date of death due to any cause
Time frame: Baseline up to 104 weeks
Adverse events (AE)
The occurrence of all adverse events (AE)
Time frame: Baseline up to 104 weeks
Serious adverse events (SAE)
The occurrence of all serious adverse events (SAE)
Time frame: Baseline up to 104 weeks
Bruton's tyrosine kinase (BTK) occupancy
The BTK occupancy in peripheral blood mononuclear cell (PMBC)
Time frame: Baseline up to 104 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2022; primary completion for Aug 2024, 21 months later.
Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 21 months is below that.
Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BTK Inhibitor TQB3702
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →